CIK 0001771917
KRTX Karuna Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Mar 18, 2024.
In brief
Karuna Therapeutics, Inc. (KRTX) has 32 SEC Form 4 filings on file from 13 insiders, the latest filed on Mar 18, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
8 open-market trades have been scored at KRTX. The newest: Stephen K. Brannan (Chief Medical Officer) sold $1.6M of stock on Mar 8, 2024, filed Mar 11, 2024, scored 10 (weak), under a 10b5-1 plan. The largest of the 8 shown: Stephen K. Brannan (Chief Medical Officer) sold $4.8M on Jan 8, 2024, scored 15 (weak), under a 10b5-1 plan.
1 member of Congress has disclosed 1 trade in KRTX under the STOCK Act. 9 Form 144 notices of planned sales are on file, the latest filed Mar 8, 2024.
Last 90 days
Signals
Open-market buys and sells at Karuna Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | Stephen K. Brannan Chief Medical Officer sell | $1.6M 5,000 shares | -11% | - | |
| 10Weak | Stephen K. Brannan Chief Medical Officer sell | $1.6M 5,000 shares | -11% | - | |
| 15Weak | Stephen K. Brannan Chief Medical Officer sell | $4.8M 15,000 shares | -28% | - | |
| 10Weak | Stephen K. Brannan Chief Medical Officer sell | $2.0M 10,000 shares | -22% | - | |
| 8Weak | Stephen K. Brannan Chief Medical Officer sell | $889k 5,000 shares | -13% | - | |
| 15Weak | Stephen K. Brannan Chief Medical Officer sell | $1.0M 5,000 shares | -27% | - | |
| 15Weak | Stephen K. Brannan Chief Medical Officer sell | $1.1M 5,000 shares | -25% | - | |
| 15Weak | Stephen K. Brannan Chief Medical Officer sell | $1.0M 5,000 shares | -25% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 8, 2024 | Brannan Stephen K. Officer | 5,000 0.01% of outstanding | $1.6M | Mar 8, 2024 | $8.4M |
| Feb 8, 2024 | Brannan Stephen K. Officer | 5,000 0.01% of outstanding | $1.6M | Feb 8, 2024 | $7.7M |
| Jan 8, 2024 | Brannan Stephen K. Officer | 15,000 0.04% of outstanding | $4.8M | Jan 8, 2024 | $3.8M |
| Dec 27, 2023 | Ignelzi Troy A. Former Affiliate | 56,631 0.15% of outstanding | $18M | Dec 27, 2023 | $15M |
| Dec 8, 2023 | Brannan Stephen K. Officer | 10,000 0.03% of outstanding | $2.0M | Dec 8, 2023 | $2.7M |
| Dec 6, 2023 | Ignelzi Troy A. Former Affiliate | 76,357 0.20% of outstanding | $16M | Dec 6, 2023 | $2.3M |
| Nov 28, 2023 | Ignelzi Troy A. Former Affiliate | 6,000 0.02% of outstanding | $1.1M | Nov 28, 2023 | $655k |
| Nov 21, 2023 | Ignelzi Troy A. Former Affiliate | 6,000 0.02% of outstanding | $1.1M | Nov 21, 2023 | $263k |
| Nov 8, 2023 | Brannan Stephen K. Officer | 5,000 0.01% of outstanding | $889k | Nov 8, 2023 | $2.7M |
Congressional trades
1 trade in KRTX disclosed by members of Congress under the STOCK Act. All congressional trades.
- Daniel S. GoldmanHouse · D-NY · last May 19, 20230 bought
1 sold
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Daniel S. Goldman House · D-NY | Sale | KRTX Karuna Therapeutics, Inc. | $1,001 to $15k | Apr 10, 2023 / May 19, 2023 39 days after the trade | Clerk |
Transactions
The newest 50 of 168 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 18, 2024 | Steven M Paul director | DDisposition to issuer Common Stock | -2,046 | $330.00 | $675k | 8,550 | Mar 18, 2024 |
| Mar 18, 2024 | Jason Parker Brown Chief Financial Officer | DDisposition to issuer Common Stock | -14,009 | $330.00 | $4.6M | 7,158 | Mar 18, 2024 |
| Mar 18, 2024 | Jeffrey M Jonas director | DDisposition to issuer Common Stock | -990 | $330.00 | $327k | 0 | Mar 18, 2024 |
| Mar 18, 2024 | William P Kane Jr Chief Commercial Officer | DDisposition to issuer Common Stock | -5,000 | $330.00 | $1.6M | 8,828 | Mar 18, 2024 |
| Mar 18, 2024 | David E. Wheadon director | DDisposition to issuer Common Stock | -990 | $330.00 | $327k | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Denice Torres director | DDisposition to issuer Common Stock | -990 | $330.00 | $327k | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Stephen K. Brannan Chief Medical Officer | DDisposition to issuer Common Stock | -36,117 | $330.00 | $12M | 6,487 | Mar 18, 2024 |
| Mar 18, 2024 | Atul Pande director | DDisposition to issuer Common Stock | -990 | $330.00 | $327k | 0 | Mar 18, 2024 |
| Mar 18, 2024 | James Healy director | DDisposition to issuer Common Stock | -32,500 | $330.00 | $11M | 990 | Mar 18, 2024 |
| Mar 18, 2024 | Christopher J Coughlin director | DDisposition to issuer Common Stock | -990 | $330.00 | $327k | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Laurie J Olson director | DDisposition to issuer Common Stock | -990 | $330.00 | $327k | 0 | Mar 18, 2024 |
| Mar 18, 2024 | William Meury President and CEO | DDisposition to issuer Common Stock | -10,342 | $330.00 | $3.4M | 19,037 | Mar 18, 2024 |
| Mar 18, 2024 | Andrew Craig Miller President of R&D | DDisposition to issuer Common Stock | -13,977 | $330.00 | $4.6M | 9,412 | Mar 18, 2024 |
| Mar 18, 2024 | James Healy director | DDisposition to issuer Common Stock | -990 | $330.00 | $327k | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Stephen K. Brannan Chief Medical Officer | DDisposition to issuer Common Stock | -6,487 | $330.00 | $2.1M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Laurie J Olson director | DDisposition to issuer Option (right to buy)derivative | -13,000 | $245.14 | $3.2M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Christopher J Coughlin director | DDisposition to issuer Option (right to buy)derivative | -25,000 | $243.35 | $6.1M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Jeffrey M Jonas director | DDisposition to issuer Option (right to buy)derivative | -19,893 | $322.73 | $6.4M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Jason Parker Brown Chief Financial Officer | DDisposition to issuer Common Stock | -7,158 | $330.00 | $2.4M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | William P Kane Jr Chief Commercial Officer | DDisposition to issuer Common Stock | -8,828 | $330.00 | $2.9M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | William Meury President and CEO | DDisposition to issuer Common Stock | -19,037 | $330.00 | $6.3M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Andrew Craig Miller President of R&D | DDisposition to issuer Common Stock | -9,412 | $330.00 | $3.1M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Atul Pande director | DDisposition to issuer Option (right to buy)derivative | -12,500 | $232.41 | $2.9M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | David E. Wheadon director | DDisposition to issuer Option (right to buy)derivative | -25,000 | $235.44 | $5.9M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Denice Torres director | DDisposition to issuer Option (right to buy)derivative | -25,000 | $225.74 | $5.6M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Steven M Paul director | DDisposition to issuer Common Stock | -8,550 | $330.00 | $2.8M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Jeffrey M Jonas director | DDisposition to issuer Option (right to buyderivative | -16,250 | $314.00 | $5.1M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Denice Torres director | DDisposition to issuer Option (right to buy)derivative | -8,500 | $201.99 | $1.7M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Andrew Craig Miller President of R&D | DDisposition to issuer Restricted Stock Unitsderivative | -15,855 | $330.00 | $5.2M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Christopher J Coughlin director | DDisposition to issuer Option (right to buy)derivative | -8,500 | $201.99 | $1.7M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | William P Kane Jr Chief Commercial Officer | DDisposition to issuer Restricted Stock Unitsderivative | -10,306 | $330.00 | $3.4M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Laurie J Olson director | DDisposition to issuer Option (right to buy)derivative | -8,500 | $201.99 | $1.7M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Atul Pande director | DDisposition to issuer Option (right to buy)derivative | -8,500 | $201.99 | $1.7M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | William Meury President and CEO | DDisposition to issuer Restricted Stock Unitsderivative | -38,688 | $330.00 | $13M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | David E. Wheadon director | DDisposition to issuer Option (right to buy)derivative | -8,500 | $201.99 | $1.7M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | James Healy director | DDisposition to issuer Common Stockindirect: By Sofinnova Synergy Master Fund, LP | -683 | $330.00 | $225k | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Steven M Paul director | DDisposition to issuer Common Stockindirect: Steve M. Paul Family 2021 Delaware Trust | -30,304 | $330.00 | $10M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Stephen K. Brannan Chief Medical Officer | DDisposition to issuer Restricted Stock Unitsderivative | -10,306 | $330.00 | $3.4M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Jason Parker Brown Chief Financial Officer | DDisposition to issuer Restricted Stock Unitsderivative | -10,306 | $330.00 | $3.4M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Andrew Craig Miller President of R&D | DDisposition to issuer Option (right to buy)derivative | -47,817 | $327.08 | $16M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Jeffrey M Jonas director | DDisposition to issuer Option (right to buyderivative | -12,500 | $232.41 | $2.9M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Stephen K. Brannan Chief Medical Officer | DDisposition to issuer Option (right to buy)derivative | -4,677 | $324.55 | $1.5M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Denice Torres director | DDisposition to issuer Option (right to buy)derivative | -5,000 | $227.04 | $1.1M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Christopher J Coughlin director | DDisposition to issuer Option (right to buy)derivative | -5,000 | $227.04 | $1.1M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | William P Kane Jr Chief Commercial Officer | DDisposition to issuer Option (right to buy)derivative | -29,937 | $137.85 | $4.1M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | William Meury President and CEO | DDisposition to issuer Option (right to buy)derivative | -63,065 | $136.81 | $8.6M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Steven M Paul director | DDisposition to issuer Common Stockindirect: Jann E Paul Revocable Trust | -10,000 | $330.00 | $3.3M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Atul Pande director | DDisposition to issuer Option (right to buy)derivative | -5,000 | $227.04 | $1.1M | 0 | Mar 18, 2024 |
| Mar 18, 2024 | Jason Parker Brown Chief Financial Officer | DDisposition to issuer Option (right to buy)derivative | -3,281 | $230.28 | $756k | 0 | Mar 18, 2024 |
| Mar 18, 2024 | James Healy director | DDisposition to issuer Common Stockindirect: By Sofinnova Venture Partners X, LP | -1,372,441 | $330.00 | $453M | 0 | Mar 18, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Stephen K. BrannanChief Medical Officer
- Jason Parker BrownChief Financial Officer
- Christopher J Coughlindirector
- James Healydirector
- Jeffrey M Jonasdirector
- William P Kane JrChief Commercial Officer
- William MeuryPresident and CEO
- Andrew Craig MillerPresident of R&D
- Laurie J Olsondirector
- Steven M Pauldirector
- Atul Pandedirector
- Denice Torresdirector
- David E. Wheadondirector
Questions about KRTX
Answered from the filings on this page, as of the latest one.
Are insiders buying KRTX?
No. In the last 90 days no insider at Karuna Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade KRTX on the open market?
Stephen K. Brannan (Chief Medical Officer) sold $1.6M of KRTX on Mar 8, 2024 and filed the Form 4 on Mar 11, 2024. InsiderTell scored 10 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at Karuna Therapeutics, Inc.?
13 people have filed a Form 4 at Karuna Therapeutics, Inc., among them Stephen K. Brannan (Chief Medical Officer), Jason Parker Brown (Chief Financial Officer), Christopher J Coughlin (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.